Could starting pills earlier improve treatment for rare blood disorder?
NCT ID NCT04304820
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether starting two oral medications (cyclosporine and eltrombopag) earlier than usual is safe and feasible for people with severe aplastic anemia, a rare condition where the immune system attacks bone marrow. Participants aged 3 and older will take these pills for up to 6 months before receiving the standard treatment with horse anti-thymocyte globulin. The goal is to see if this early start helps patients tolerate the full treatment better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclosporine and eltrombopag
- What this could lead to
- If successful, this approach could make the standard treatment for severe aplastic anemia safer and more manageable by starting oral medications earlier.
- What could go wrong
- This is a small, early-phase trial (phase 2) with only 80 participants, so results may not apply to everyone. There are risks from the drugs, including side effects like kidney problems or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Half-Matched stem cell transplant offers hope for children with blood disorders
- New transplant approach aims to tame bone marrow failure
- New hope for older adults with rare blood disorder: safer transplant regimen under study
- New drug combo shows promise for rare bone marrow failure
- New drug combo shows promise for rare blood disorder